HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection

Akbar, Sheikh Mohammad Fazle; Al‐Mahtab, Mamun; Uddin, Mohammad Helal; Khan, Md. Sakirul Islam

doi:10.1016/s1499-3872(13)60057-0

Cited by 12 publications

(6 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A combination of HBsAg- and HBcAg-based vaccines has been evaluated in research of finding proper strategies for chronic hepatitis B patients. Their incorporation can form a highly immunogenic structure to enhance humoral immunity against both antigens ( 69 ). In our study, in silico assessments of the designed vaccine showed the feasibility of humoral and cellular immunogenicity while declaring no allergenicity effect.…”

Section: Discussionmentioning

confidence: 99%

Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus

et al. 2020

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is a global virus responsible for a universal disease burden for millions of people. Various vaccination strategies have been developed using viral vector, nucleic acid, protein, peptide, and virus-like particles (VLPs) to stimulate favorable immune responses against HBV. Given the pivotal role of specific immune responses of hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) in infection control, we designed a VLP-based vaccine by placing the antibody-binding fragments of HBsAg in the major immunodominant region (MIR) epitope of HBcAg to stimulate multilateral immunity. A computational approach was employed to predict and evaluate the conservation, antigenicity, allergenicity, and immunogenicity of the construct. Modeling and molecular dynamics (MD) demonstrated the folding stability of HBcAg as a carrier in inserting Myrcludex and "a" determinant of HBsAg. Regions 1-50 and 118-150 of HBsAg were considered to have the highest stability to be involved in the designed vaccine. Molecular docking revealed appropriate interactions between the B cell epitope of the designed vaccine and the antibodies. Totally, the final construct was promising for inducing humoral and cellular responses against HBV.

show abstract

Section: Discussionmentioning

confidence: 99%

Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, these drugs are not able to degrade all forms of DNA virus, such as cccDNA, so replication of HBV and liver damage still occur in the off-treatment period. In addition, treatment of HBV infection with antiviral drugs can lead to toxicity and resistance of the virus in long-term treatment [7].…”

Section: A Rt I C L E I N F O Abstractmentioning

confidence: 99%

“…Whereas, immunogenicity of HBcAg is higher than that of HBsAg. HBcAg-based vaccine can induce both HBsAg-CTL and HBcAg-CTL in the liver [7].…”

Section: A Rt I C L E I N F O Abstractmentioning

confidence: 99%

Soluble expression and purification of hepatitis B core antigen (HBcAg) subgenotype B3 in Escherichia coli using thioredoxin fusion tag

Waty¹,

Mustopa²,

Suharsono³

et al. 2017

APJTD

View full text Add to dashboard Cite

“…Epitopes of both HBsAg and HBV core were loaded on dendritic cells, and epitope-pulsed dendritic cells were used in chronic hepatitis B patients. The results of the epitope study demonstrated the potent antiviral effects of dendritic cell vaccines that contain HBsAg and HBV core epitopes [ 29 ]. A phase III clinical trial of an HBsAg/HBV core-based therapeutic vaccine, administered through the nasal and subcutaneous routes, is currently underway in chronic hepatitis B patients [ 29 ].…”

Section: Targeting Therapies and Vaccines Against Hbv Corementioning

confidence: 99%

HBV Core Protein Enhances Cytokine Production

Sasaki

Nakamura

et al. 2015

Diseases

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection, a cause of hepatocellular carcinoma (HCC), remains a serious global health concern. HCC development and human hepatocarcinogenesis are associated with hepatic inflammation caused by host interferons and cytokines. This article focused on the association between the HBV core protein, which is one of the HBV-encoding proteins, and cytokine production. The HBV core protein induced the production of interferons and cytokines in human hepatoma cells and in a mouse model. These factors may be responsible for persistent HBV infection and hepatocarcinogenesis. Inhibitors of programmed death (PD)-1 and HBV core and therapeutic vaccines including HBV core might be useful for the treatment of patients with chronic HBV infection. Inhibitors of HBV core, which is important for hepatic inflammation, could be helpful in preventing the progression of liver diseases in HBV-infected patients.

show abstract

HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection

Cited by 12 publications

References 53 publications

Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus

Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus

Soluble expression and purification of hepatitis B core antigen (HBcAg) subgenotype B3 in Escherichia coli using thioredoxin fusion tag

HBV Core Protein Enhances Cytokine Production

Contact Info

Product

Resources

About